Literature DB >> 12131918

Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole.

J S R Oliveira1, F R Kerbauy, A L Colombo, D M M Bahia, G S Pinheiro, M R R Silva, M S S Ribeiro, G Raineri, J Kerbauy.   

Abstract

Fungal infection is one of the most important causes of morbidity and mortality in bone marrow transplant (BMT) recipients. The growing incidence of these infections is related to several factors including prolonged granulocytopenia, use of broad-spectrum antibiotics, conditioning regimens, and use of immunosuppression to avoid graft-versus-host disease (GvHD). In the present series, we report five cases of invasive mold infections documented among 64 BMT recipients undergoing fluconazole antifungal prophylaxis: 1) A strain of Scedosporium prolificans was isolated from a skin lesion that developed on day +72 after BMT in a chronic myeloid leukemic patient. 2) Invasive pulmonary aspergillosis (Aspergillus fumigatus) was diagnosed on day +29 in a patient with a long period of hospitalization before being transplanted for severe aplastic anemia. 3) A tumoral lung lesion due to Rhizopus arrhizus (zygomycosis) was observed in a transplanted patient who presented severe chronic GvHD. 4) A tumoral lesion due to Aspergillus spp involving the 7th, 8th and 9th right ribs and local soft tissue was diagnosed in a BMT patient on day +110. 5) A patient with a history of Ph1-positive acute lymphocytic leukemia exhibited a cerebral lesion on day +477 after receiving a BMT during an episode of severe chronic GvHD. At that time, blood and spinal fluid cultures yielded Fusarium sp. Opportunistic infections due to fungi other than Candida spp are becoming a major problem among BMT patients receiving systemic antifungal prophylaxis with fluconazole.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12131918     DOI: 10.1590/s0100-879x2002000700005

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  6 in total

1.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 2.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 3.  Anti dermatophytic therapy--prospects for the discovery of new drugs from natural products.

Authors:  Luciana Arantes Soares; Janaína de Cássia Orlandi Sardi; Fernanda Patrícia Gullo; Nayla de Souza Pitangui; Liliana Scorzoni; Fernanda Sangalli Leite; Maria José Soares Mendes Giannini; Ana Marisa Fusco Almeida
Journal:  Braz J Microbiol       Date:  2014-03-10       Impact factor: 2.476

4.  In vitro activity of chlorogenic acid against Aspergillus fumigatus biofilm and gliotoxin production.

Authors:  Jin-Liang Kong; Jing Luo; Bing Li; Bi-Ying Dong; Hong Huang; Ke Wang; Li-Hong Wu; Yi-Qiang Chen
Journal:  Exp Ther Med       Date:  2017-04-07       Impact factor: 2.447

5.  Update on the treatment of disseminated fusariosis: Focus on voriconazole.

Authors:  Marta Stanzani; Fabio Tumietto; Nicola Vianelli; Michele Baccarani
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

Review 6.  Fusarium infection: report of 26 cases and review of 97 cases from the literature.

Authors:  Maged Muhammed; Theodora Anagnostou; Athanasios Desalermos; Themistoklis K Kourkoumpetis; Herman A Carneiro; Justin Glavis-Bloom; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Medicine (Baltimore)       Date:  2013-11       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.